Company · Healthtech & Bio

Libera Bio

liberabio.com ↗ ·Santiago de Compostela ·Seed

Libera Bio is a biopharmaceutical company developing a new class of cancer therapeutics that reach 'undruggable' intracellular targets, built on its proprietary MPN Technology (Multifunctional Polymeric Nanoparticles) that protects whole antibodies, nanobodies, small molecules and PROTACs in the bloodstream and delivers them inside tumour cells. A 2020 spin-off of the University of Santiago de Compostela out of Prof. Maria Jose Alonso's nanomedicine lab, it is seed-stage and focused on KRAS-mutant cancers such as pancreatic ductal adenocarcinoma, with partnerships including ImmunoPrecise Antibodies and EVQLV. It is headquartered in Santiago de Compostela (Galicia) with a US office in Larchmont, New York.

Founded
2020
Founders
3
News
5
Rounds
2
Investors
6
SectorsBiotech, Oncology, Nanomedicine, Drug Delivery, Pharmaceuticals, Deeptech Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 22 Aug 2026

Founders

Desiree Teijeiro Osorio
Co-Founder & Chief Operating Officer
Maria Jose Alonso Fernandez
Founder & Chief Scientific Officer
Olivier R. Jarry
Co-Founder & CEO

Global models

No comparables on record yet.

Investors 6

CDTI Innvierte
www.cdti.es
Investor Spain
Nowture
Investor Spain
ROSP Corunna Participaciones Empresariales
Investor Spain
Semola Tech Ventures
Investor Spain
Unixest (Sociedade Xestora de Intereses da USC)
Investor Spain
Xesgalicia (Galicia Innova Tech)
www.xesgalicia.gal
Investor Spain

Funding rounds 2

Seed · €1.3M
Libera Bio, a 2020 spin-off from the University of Santiago de Compostela developing its MPN Technology to deliver whole antibodies to intra…
2022-07-04
Seed · €289.5K
XesGalicia, through its Galicia InnovaTech fund, invested €289,500 in a capital increase at Libera Bio, a University of Santiago de Composte…
2022-01-24

News & media 5

Start typing to search across everything.
↑↓ navigate↵ openesc close